Please ensure Javascript is enabled for purposes of website accessibility

Amgen Leaves Investors With Mixed Emotions

By Cory Renauer - Updated Apr 23, 2019 at 11:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Strong results from last year were tempered by a soft outlook for 2019.

Amgen's (AMGN 0.94%) recently reported results for the fourth quarter of 2019 left investors feeling more mixed up than usual. Sales of important new products continued to exceed expectations, but the company also predicted a slight decline on the top and bottom lines this year.

Amgen results: The raw numbers

Metric Q4 2018 Q4 2017 Year-Over-Year Change
Revenue $6.2 billion $5.8 billion 7%
Income from operations $2.4 billion $2.2 billion 6%
Earnings per share $3.01 ($5.89) N/A

Data source: Amgen.

What happened with Amgen this quarter?

Enbrel is still Amgen's top-selling product, but sales of the anti-inflammatory injection fell 8% in the fourth quarter compared to the previous year. Despite Enbrel's slide, total product sales rose 8% with help from a handful of younger drugs. Here's what pushed the needle forward: 

  • The initial launch of the company's new migraine headache prevention drug is progressing better than expected. The company recorded $95 million in Aimovig sales despite heavily discounting the drug to maintain an early lead over competing treatments from Eli Lilly (LLY 4.12%) and Teva Pharmaceuticals (TEVA 0.91%).
  • Sales of Repatha are also responding well to deep discounts. Despite a lower net price, increased volume helped drive sales of the cholesterol-reducing treatment 62% higher to $159 million.
  • The company's bone density drug, denosumab, added $1.1 billion to the company's top line, which was 15% more than the same period a year earlier.
  • Sales of Parsabiv, which launched at the beginning of 2018, generated $108 million during the fourth quarter. Sales of the hyperthyroidism treatment for patients with chronic kidney disease are being driven by dialysis providers of all sizes. 
  • Amgen's first bi-specific antibody has been gaining traction since it earned approval to treat leukemia patients that are nearly in remission in order to keep the disease from roaring back. Blincyto sales rose 37% on year to $63 million.
  • Sales of the biotech's treatment for relapsed multiple myeloma finally achieved a $1 billion annualized run rate. Kyprolis earned approval for a more convenient weekly dosing schedule in October that helped it along.

The fourth quarter was a quiet one for Amgen's development pipeline. The National Medical Products Administration of China approved Repatha to reduce the risk of heart attacks and strokes for adults with cardiovascular disease. In December, Nplate earned approval to treat pediatric patients with immune thrombocytopenia and the company submitted another application to treat adults with the same condition.

Gloved hand holding a beaker full of hundred-dollar bills.

Image source: Getty Images.

What management had to say

Amgen CEO Robert A. Bradway was even more upbeat than usual about the company's fourth-quarter performance and ability to keep performing for the long run. He said, "Through our continued solid operating performance in 2018, we met and exceeded our long-term financial commitments. Looking to the future, we are encouraged by our long-term growth prospects driven by our portfolio of newer products, pipeline and ongoing success in international expansion."

The continued decline of Enbrel and the eventual decline of Neulasta will still hurt a great deal over the next several years, but Amgen's got what it needs to maintain those commitments. Operations generated $10.6 billion in free cash flow, and the company used just $3.5 billion to make dividend payments last year.

Scientist looking at a capsule.

Image source: Getty Images.

Looking forward

In 2019, Amgen expects total revenue to contract slightly from $23.7 billion to a range between $21.8 billion and $22.9 billion. On the bottom line, adjusted earnings per share are expected to slide slightly from $14.40 in 2018 to a range between $13.10 and $14.30 this year.

Amgen will have to compete for market share with Eli Lilly and Teva, but Aimovig appears to be holding on to its early lead in the migraine prevention race. During the fourth quarter, the company raised the number of patent starts since it launched to 150,000 from 100,000 at the end of September.

That means there are probably already enough people using Aimovig to drive annual sales of the monthly injection to $1 billion, and it's just getting started. Don't be surprised if Amgen raises its revenue expectations later this year.

Check out the latest Amgen earnings call transcript.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$245.37 (0.94%) $2.28
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$7.74 (0.91%) $0.07
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$325.62 (4.12%) $12.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.